Also, for SCLC, the role and timing of thoracic irradiation and prophylacticcranial irradiation (PCI) for the limited and extensive stages will be discussed.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Lung cancer is divided into two subgroups concerning its natural course and treatment strategies as follows: non-small cell lungcancer (NSCLC) and small cell lung cancer (SCLC).
📊
Key Findings & Data:In this review, for NSCLC, the role of stereotactic body radiation therapy (SBRT) inearly-stage, chemoradiation in the locally advanced stage, post-operative radiotherapy for patients with high risk after surgery andradiotherapy for metastatic disease will be discussed.
💡
Conclusion & Impact:Also, for SCLC, the role and timing of thoracic irradiation and prophylacticcranial irradiation (PCI) for the limited and extensive stages will be discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Lung cancer is divided into two subgroups concerning its natural course and treatment strategies as follows: non-small cell lungcancer (NSCLC) and small cell lung cancer (SCLC). In this review, for NSCLC, the role of stereotactic body radiation therapy (SBRT) inearly-stage, chemoradiation in the locally advanced stage, post-operative radiotherapy for patients with high risk after surgery andradiotherapy for metastatic disease will be discussed. Also, for SCLC, the role and timing of thoracic irradiation and prophylacticcranial irradiation (PCI) for the limited and extensive stages will be discussed.
🔖
Cite This Article
UZEL, E. K., FİGEN, M., UZEL, Ö. (2019). Radiotherapy in Lung Cancer: Current and Future Role. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 53 - Sayı: 4, 353–360. https://ajindex.com/articles/363999
Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434–41
Uzel EK, Abacıoğlu U. Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? Balkan Med J 2015;32:8–16
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94–100
Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography imageguided radiotherapy. J Thorac Oncol 2012;7:1382–93
Liu F, Tai A, Lee P, Biswas T, Ding GX, El Naqa I, et al. Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. Radiother Oncol 2017;122:286–94
Stephans KL, Woody NM, Reddy CA, Varley M, Magnelli A, Zhuang T, et al. Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I NonSmall Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2018;100:462– 9
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070–6
Timmerman RD, Hu C, Michalski J, Straube W, Galvin J, Johnstone D, et al. Long-term results of RTOG 0236: A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014;90:S30
Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys 2015;93:989–96
Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:3290–6
Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, et al. Comparative effectiveness of 5 treatment strategies for earlystage non-small cell lung cancer in the elderly. Int J Ra